The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

BZ Group
  • 3.0 (4)
  • Life Sciences
  • Daily

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts, deal intelligence, and the daily newsletter at https://thepharmacloseout.com/. Host voices are AI-created.

  1. 6h ago

    Daily Roundup | Genmab's Cancer Survival Gain & Lilly's Retatrutide Dose Trade-Off

    This is the October 28 edition of The Pharma Closeout, released October 29. Genmab's investigational petosemtamab combination improves survival against pembrolizumab alone in a first-line head-and-neck cancer trial, while Lilly's retatrutide raises a dose-choice question after greater weight loss and more adverse-event discontinuations than Ozempic (semaglutide) 2 mg in type 2 diabetes. Geron stops imetelstat's myelofibrosis trial; AbbVie files etentamig for multiple myeloma using previously reported CERVINO results; and Replimune reports early launch activity for TUDRIQEV (vusolimogene oderparepvec-wtpg) in melanoma. FDA's draft individualized gene-editing framework, CMS's planned gene-therapy access expansion and HHS's proposed conditional peptide-compounding policy remain distinct developments. GSK's sales mix shifts toward specialty medicines, and FDA staff questions set up the October 30 advisory committee on Sydnexis's atropine for pediatric myopia. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.

  2. 1d ago

    Daily Roundup | Artiva Ends AlloNK, Cuts 94% of Staff & Ferring Agrees to Buy Gameto

    Artiva ends AlloNK and cuts about 94% of staff after a risk-benefit review covering durability and two separately assessed deaths. Ferring agrees to acquire Gameto for up to $1.3825 billion subject to milestones, before Fertilo's pivotal fertility trial reports. Pfizer's ELREXFIO (elranatamab) meets a Phase 3 myeloma goal with higher rates of severe infections; AstraZeneca and Daiichi Sankyo gain EU approval for Enhertu (trastuzumab deruxtecan) in postoperative HER2-positive early breast cancer; Novartis discontinues remibrutinib in generalized myasthenia gravis for futility. Also: Teva closes its BioXcel asset deal for IGALMI (dexmedetomidine) and the pending at-home BXCL501 program; Vanda's NEREUS (tradipitant) reduces vomiting in a single-dose semaglutide challenge; and Kiniksa raises its ARCALYST (rilonacept) sales forecast. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.

  3. 2d ago

    Daily Roundup | BioNTech/DualityBio Breast ADC Gain Called Modest & Merck's sac-TMT Survival Edge Under FDA Review

    October 26, 2026 edition, released October 27. Recorded October 26: references to today mean October 26, and tomorrow means October 27. BioNTech and DualityBio's breast cancer ADC beat chemo in Phase 3, yet the companies call the gain modest. Merck and Kelun's sac-TMT showed interim median overall survival of 19.0 vs 12.1 months in endometrial cancer after platinum and immunotherapy and is under FDA priority review. Also: Keytruda (pembrolizumab) alone in first-line dMMR endometrial cancer; FDA approval of Talzenna (talazoparib) plus Xtandi (enzalutamide) for adults with metastatic, androgen pathway modulation-naive or -sensitive prostate cancer with HRR mutations detected by an FDA-authorized test; BMS/SystImmune's iza-bren in EGFR-mutated lung cancer; GSK/Hansoh's ris-rez in osteosarcoma; and Corxel US/Amanat's proposed deal that would help fund oral GLP-1 CX11. Sources:- SEC (BioNTech Exhibit 99.1): DYNASTY-Breast02 topline Phase 3 results for trastuzumab pamirtecan — October 26, 2026 — https://www.sec.gov/Archives/edgar/data/0001776985/000177698526000074/a991261025_bntxdbxtpamxtop.htm- FDA: Approval of fam-trastuzumab deruxtecan-nxki in HR-positive HER2-low or HER2-ultralow metastatic breast cancer — January 2025 — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2- Merck: TroFuse-005 sacituzumab tirumotecan endometrial results and FDA priority review — October 26, 2026 — https://www.merck.com/news/sacituzumab-tirumotecan-sac-tmt-reduced-the-risk-of-death-by-32-and-the-risk-of-disease-progression-or-death-by-41-compared-to-chemotherapy-in-certain-patients-with-advanced-or-recurrent-endometrial/- Merck: KEYNOTE-C93 Keytruda monotherapy in dMMR endometrial cancer — October 26, 2026 — https://www.merck.com/news/keytruda-pembrolizumab-as-monotherapy-reduced-the-risk-of-disease-progression-or-death-by-43-for-certain-patients-with-advanced-or-recurrent-endometrial-cancer-with-mismatch-repair-deficient/- FDA: Approval of talazoparib with enzalutamide in metastatic androgen pathway modulation-naive or -sensitive prostate cancer — October 26, 2026 — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive- Bristol Myers Squibb: PANKU-Lung01 Phase 3 results for izalontamab brengitecan — October 26, 2026 — https://news.bms.com/news/corporate-financial/2026/Izalontamab-Brengitecan-Iza-Bren-Doubles-Median-Progression-Free-Survival-in-Patients-with-Previously-Treated-EGFR-Mutated-Non-Small-Cell-Lung-Cancer-Compared-to-Chemotherapy-in-the-Phase-3-PANKU-Lung01-Study/default.aspx- FDA: Approval of amivantamab-vmjw with carboplatin and pemetrexed after EGFR TKI — September 19, 2024 — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19- GSK: ARTEMIS-011 ris-rez in relapsed osteosarcoma in China — October 26, 2026 — https://www.gsk.com/en-gb/media/press-releases/ris-rez-reduced-risk-of-disease-progression-or-death-by-67-versus-chemotherapy-in-patients-with-relapsed-osteosarcoma-in-china/- SEC (Exhibit 99.1): Corxel and Amanat proposed business combination and financing — October 26, 2026 — https://www.sec.gov/Archives/edgar/data/2112457/000121390026112236/ea030895401ex99-1.htm- FDA: Approval of talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer — June 20, 2023 — https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate

  4. 3d ago

    Week in Review | Amgen's Survival Gain, Roche's KRAS Challenge & Gilead's IBD Deal

    Sunday, October 25 edition, released Monday, October 26 with the SANOVO update. Amgen's Imdelltra plus AstraZeneca's Imfinzi extended median survival to 21.1 months from 12.7 in extensive-stage small-cell lung cancer maintenance, while Roche's divarasib beat pooled KRAS G12C comparators. AstraZeneca's Sone-Ve delivered a gastric-cancer survival win beside a missed progression endpoint; SANOVO then showed Tagrisso plus Orpathys improved progression-free survival in untreated, biomarker-selected patients in China. Gilead's $1.275 billion PepStar IL-23 deal and AbbVie's Skyrizi Crohn's approval lead gastroenterology, with hematology, immunology, diagnostics and biotech investment rules rounding out the full Week in Review. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.

  5. 4d ago

    Daily Roundup | Remibrutinib Cuts MS Relapses & Iza-bren Improves Breast Cancer PFS

    Delayed release on October 24, 2026 of the Friday, October 23 edition. News and relative-date references are as of October 23. Novartis's investigational remibrutinib cut MS relapse rates 35.2% and 31.2% versus teriflunomide; Biokin's Bristol Myers Squibb/SystImmune-partnered iza-bren improved breast cancer PFS. Jazz/BeOne's Ziihera (zanidatamab), licensed from Zymeworks, has mature gastroesophageal survival data, while Tango reports pancreatic cancer responses with vopimetostat and Revolution Medicines' daraxonrasib. Johnson & Johnson's Tecvayli (teclistamab) moves earlier in European myeloma treatment, as we examine BMS's zola-cel safety in MS and Alnylam's brezosiran target engagement in Huntington's. Plus Bolt's Prana acquisition and Treasury's proposed biotech investment rules. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

  6. 5d ago

    UEG Week 2026 Debrief: Takeda's Treat-to-Target Test & Duvakitug's 44-Week TL1A Read

    The Pharma Closeout's UEG Week 2026 Debrief covers the readouts from United European Gastroenterology Week in Barcelona that matter for drug, device and payer strategy. Takeda's VERDICT, the first randomized treat-to-target strategy trial in ulcerative colitis, and the new STRIDE-III guidance sharpen what IBD treatment should aim at, and what that means for how therapies win switches. Then the orals (Abivax's obefazimod ahead of its NDA, Gilead's emvistegrast dose curve, J&J's icotrokinra), the TL1A race with Teva and Sanofi's first 44-week duvakitug data, the incumbents' franchise defense from AbbVie and J&J, Tremfya at week 48 in Crohn's with fistulas, and a gastroparesis drug heading to Phase 3. Plus what to watch: AbbVie's October 30 results, AASLD from November 5 and the November 27 PBC decision. 0:00 Cold open and introduction 0:50 Story of the Congress: the target, not the molecule (Takeda's VERDICT, STRIDE-III, PROFILE) 5:06 The orals: obefazimod, emvistegrast, icotrokinra and OD-001 8:38 The TL1A race: Teva and Sanofi's duvakitug 10:01 Franchise defense: AbbVie, J&J, Spyre and the biosimilar squeeze 13:26 The IL-23 incumbents: Tremfya in fistulizing Crohn's, Skyrizi's subcutaneous induction 15:26 Beyond IBD: gastroparesis, EoE and the liver 17:27 What to watch: AbbVie's results, AASLD and the PBC decision Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

  7. 6d ago

    Daily Roundup | Merck-Moderna mRNA Cuts Melanoma Recurrence or Death & AbbVie HS Drug Hits Phase 3 Goal

    October 22, 2026 edition, released October 23. Reporting reflects the October 22 research cutoff. Merck and Moderna's investigational intismeran autogene, added to Keytruda (pembrolizumab) after surgery for high-risk cutaneous melanoma, posted a 0.58 hazard ratio for recurrence or death versus placebo plus Keytruda; overall survival is immature. AbbVie's investigational lutikizumab beat placebo in a Phase 3 hidradenitis suppurativa trial, 31.4% versus 23.4% on HiSCR75. The daily roundup covers BioNTech's planned pairing of pumitamig with Gilead's Trodelvy (sacituzumab govitecan), Menarini subsidiary Stemline's GIM-621 license from Georgiamune, Cencora's American Oncology Network deal and Roche's removal of RG6540 from its Phase 1 pipeline. It also covers Krystal Biotech's Vyjuvek (beremagene geperpavec) storage update, Biohaven's statement, reported by Dow Jones, that FDA accepted its Vyglxia resubmission, and QIAGEN's agreed EQT-led acquisition. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

  8. Oct 22

    Daily Roundup | Brepocitinib Holds Uveitis Control Off Steroids; Oral Olorofim Shows Far Fewer Kidney Events

    October 21, 2026 edition, released October 22. Relative dates in the audio refer to October 21. Roivant's Priovant reports two positive Phase 3 trials of oral brepocitinib in non-infectious uveitis, run through a mandatory steroid taper. F2G and Shionogi add kidney, liver and hospital-stay detail from olorofim's OASIS trial, where survival was noninferior rather than better. Also in the daily roundup: Alcon completes its Neurotech acquisition, the European Commission approves perioperative Keytruda plus Padcev regardless of cisplatin eligibility, Summit and ECOG-ACRIN set up a trial of ivonescimab in biliary tract cancer, Roche discloses fenebrutinib lesion imaging ahead of its MSToronto presentation, TG releases data on a single-infusion Briumvi start, OpenAI acquires Orchestra Bio, and FDA's warning letter to Baxter becomes public. Sources:https://www.biospace.com/press-releases/roivant-and-priovant-announce-positive-results-in-clarity-1-and-clarity-2-phase-3-trials-for-brepocitinib-in-non-infectious-uveitis-niuhttps://www.sec.gov/Archives/edgar/data/1635088/000114036126034854/ef20081283_ex99-1.htmhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5023a17b-e96a-67d4-e063-6394a90a14a7https://www.shionogi.com/global/en/news/2026/10/e20261021_3.htmlhttps://www.biospace.com/press-releases/alcon-acquires-neurotech-and-encelto-the-only-fda-approved-treatment-for-mactel-type-2https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-perioperative-treatment-for-adults-with-resectable-muscle-invasive-bladder-cancer-mibc/https://www.prnewswire.com/news-releases/akeso-announces-summit-therapeutics-and-ecog-acrin-cancer-research-group-enter-into-phase-iiiii-clinical-trial-collaboration-to-evaluate-ivonescimab-in-first-line-biliary-tract-cancer-302915469.htmlhttps://www.roche.com/media/releases/med-cor-2026-10-21https://clinicaltrials.gov/study/NCT04544449https://www.tgtherapeutics.com/wp-content/uploads/2026/10/ENHANCE-600-mg_ECTRIMS-2026_Final-Poster_PDF.pdfhttps://openai.com/index/openai-to-acquire-orchestra-bio/https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-international-inc-733231-09292026https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-first-pd-1-inhibitor-plus-antibody-drug-conjugate-regimen-for-adults-with-cisplatin-ineligibl/https://www.roche.com/media/releases/med-cor-2026-09-30

See All (194)

Ratings & Reviews

3
out of 5
4 Ratings

About

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts, deal intelligence, and the daily newsletter at https://thepharmacloseout.com/. Host voices are AI-created.

Information

You Might Also Like